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Abstract
Background:  Chlamydia pneumoniae antigens, nucleic acids, or intact organisms have been
detected in human atheroma. However, the presence of antibody does not predict subsequent
cardiovascular (CV) events. We performed a systematic review to determine whether the
detection of C. pneumoniae DNA in peripheral blood mononuclear cells (PBMC) was associated
with CV disease.
Methods: We sought studies of C. pneumoniae DNA detection in PBMC by polymerase chain
reaction (PCR) among patients with CV disease or other clinical conditions. We pooled studies in
which CV patients were compared with non-diseased controls. We analyzed differences between
studies by meta-regression, to determine which epidemiological and technical characteristics were
associated with higher prevalence.
Results: Eighteen relevant studies were identified. In nine CV studies with control subjects, the
prevalence of circulating C. pneumoniae DNA was 252 of 1763 (14.3%) CV patients and 74 of 874
(8.5%) controls, for a pooled odds ratio of 2.03 (95% CI: 1.34, 3.08, P < 0.001). Prevalence was not
adjusted for CV risk factors. Current smoking status, season, and age were associated with C.
pneumoniae DNA detection. High prevalence (>40%) was found in patients with cardiac, vascular,
chronic respiratory, or renal disease, and in blood donors. Substantial differences between studies
were identified in methods of sampling, extraction, and PCR targets.
Conclusions: C. pneumoniae DNA detection was associated with CV disease in unadjusted case-
control studies. However, adjustment for potentially confounding measures such as smoking or
season, and standardization of laboratory methods, are needed to confirm this association.
Background
Since Fabricant et al demonstrated infection-induced
atherosclerosis in chickens in 1978 [1], a number of virus-
es and bacteria have been investigated for a possible asso-
ciation with human atherosclerosis. The majority of
investigators have focused on the putative role of the
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gram-negative, intracellular bacterium Chlamydia pneumo-
niae in atherosclerosis [2–4].
Indirect evidence of a possible association between C.
pneumoniae and atherosclerosis was first found by Saikku
et al in 1988, who measured circulating C. pneumoniae-
specific IgG antibody by micro-immunofluorescence in
patients with acute or chronic heart disease [5]. In a review
of the existing literature as of 1997, Danesh et al found a
relationship between C. pneumoniae IgG seroprevalence
and heart disease, primarily based on case-control studies
[6]. In a subsequent meta-analysis that pooled 15 pro-
spective studies, Danesh et al found no over-all relation-
ship between C. pneumoniae IgG seroprevalence and
subsequent cardiovascular events after adjusting for age,
gender, smoking, and socio-economic status [7]. Similar-
ly, in 3,168 patients enrolled in the Heart Outcomes Pre-
vention and Evaluation study, we found no consistent
relationship between C. pneumoniae IgG or IgA positivity
and subsequent cardiovascular events during 4.5 years of
follow-up (Smieja et al, unpublished). In aggregate, these
sero-epidemiologic data suggest that C. pneumoniae is not
an important cause of cardiovascular disease.
Pathological studies of arterial wall provide more direct
evidence for an association between C. pneumoniae and
human atherosclerosis, albeit with marked variability be-
tween laboratories [8]. Using electron microscopy,
chlamydia-like elementary bodies have been observed in
atheroma [9]. Using immunohistochemistry with specific
monoclonal antibodies, C. pneumoniae antigen has been
detected in atheroma and localized to macrophages, en-
dothelial cells, and smooth muscle cells in vitro and in vi-
vo[10–12]. Polymerase chain reaction (PCR) has been
used to amplify C. pneumoniae-specific nucleic acids with-
in atheroma, and localization to abnormal but not to nor-
mal arterial wall has been demonstrated [13]. Fifteen
arterial specimens were analyzed by nine laboratories us-
ing 16 PCR techniques, with the detection of C. pneumoni-
ae DNA in at least one specimen by six of nine laboratories
[14]. Over-all, 9% of specimens were positive, suggesting
low copy number and large inter-laboratory variation in
extraction efficiency, sensitivity, or specificity of the PCR
methods. Using reverse transcriptase (RT)-PCR, C. pneu-
moniae-specific RNA has been demonstrated in lesions,
implying that the bacteria are viable and transcribing spe-
cific RNA [15]. Finally, in a small number of patients, via-
ble C. pneumoniae have been cultured from cardiac [16]
and carotid vessels [17,18] and from aortic aneurysms
[19]. In aggregate, these molecular data demonstrate that
C. pneumoniae or its antigens and nucleic acids are found
in human atheroma.
Thus, a major discrepancy exists between the widespread
detection of C. pneumoniae in atheroma, and the lack of at-
tributable risk in sero-epidemiologic studies. A key ques-
tion is whether C. pneumoniae IgG or IgA correlates with
the presence of C. pneumoniae in plaque. Campbell found
no correlation between C. pneumoniae IgG by micro-im-
munofluorescence and the presence of C. pneumoniae in
plaque. Similarly, Maass [20] and Berger [21] found no
correlation between serology and DNA in plaque. Thus, C.
pneumoniae serology may be a poor predictor for C. pneu-
moniae in plaque, and the lack of a prospective association
between serology and cardiovascular events may therefore
not be relevant. Hence, the question of whether C. pneu-
moniae in plaque contributes to atherosclerotic initiation
or progression or to clinical events remains unanswered.
In this paper, we review studies of C. pneumoniae DNA de-
tection in peripheral blood mononuclear cells (PBMC), to
determine whether this would be a superior epidemiolog-
ic tool for prospective studies assessing the contribution
of infection to human cardiovascular disease.
Methods
We performed a MEDLINE search (1980–2002 inclusive)
using the terms "Chlamydia pneumoniae", "Chlamydophila
pneumoniae", "Chlamydia TWAR", "atherosclerosis" as ma-
jor headings or text words combined with "nucleic acid"
or "polymerase chain reaction" as text words. We sought
human studies in which nucleic acids, antigen, or intact C.
pneumoniae were detected in peripheral blood. We also
sought studies in which these were correlated with the tis-
sue presence of C. pneumoniae by antigen detection, nucle-
ic acid amplification, or culture. For sentinel papers, we
searched for citations in the Science Citation Index to
identify recent papers using similar technologies. We
searched through the citations of found manuscripts as
well as searching the abstracts of infectious diseases,
microbiology and cardiology meetings between 1998 and
2002. Studies with control patients were entered into Re-
view Manager 4.04 and a pooled odds ratio was calculated
using a random effects model.
Results
We identified 18 studies in which circulating blood C.
pneumoniae DNA detection was undertaken, as summa-
rized in Tables 1 and 2. The majority of these involved car-
diovascular patients, and the remainder examined
respirology or nephrology patients or blood donors.
Prevalence in cardiovascular studies with control groups
Boman et al, working in Sweden, first demonstrated the
detection of C. pneumoniae DNA in PBMC of cardiac pa-
tients [22]. They found a prevalence of 59% of patients
undergoing coronary angiography, using a nested PCR
targeting an outer membrane protein (ompI) gene. Preva-
lence was also high in middle-aged blood donors (46%),
with a higher prevalence in cases than controls.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/21
Page 3 of 10
(page number not for citation purposes)
Table 1: Studies with controls of Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells
Reference Country Cases Prevalence 
(%)
Controls Prevalence 
(%)
Blood sampling DNA 
Extraction
PCRa target
Berger, 2000 
[21]
Germany Vascular surgery 12 of 60 
(20.0)
Not stated 7 of 51 
(13.7)
4 mL EDTA 
blood
Phenol-
chloroform
16S rDNA
Boman, 1998 
[22]
Sweden Coronary Angiography 60 of 101 
(59.4)
Blood 
donors
24 of 52 
(46.1)
10 mL EDTAb 
blood
Phenol-
chloroform
Nested 
MOMPc
Da Costa, 
2000 
(abstract)
Germany Coronary Angioplasty 
and antibiotics
14 of 233 
(6.0)
Blood 
donors
5 of 200 
(2.5)
Not stated QIAamp or 
phenol-
chloroform
Not stated
Freidank, 2000 
[23]
Germany Carotid atherosclerosis 10 of 60 
(16.7)
Medical 
students, 
patients
0 of 109 
(0.0)
10 mL whole 
blood
QIAamp Nested pstI 
cloned frag-
ment
Kaul, 2000 
[24]
United 
States
Coronary artery disease 13 of 28 
(46.4)
Blood 
donors
5 of 19 
(26.3)
20–30 mL 
EDTA, CD3+ 
cell selection
SDS-pro-
teinase K
Nested 
MOMP HSPd-
60
Maraha, 2001 
[25]
Netherlands Aortic aneurysm 18 of 88 
(20.5)
Healthy 
controls
8 of 88 
(9.1)
EDTA blood QIAamp 16S rDNA
Sessa, 2000 
[26]
Italy Unstable angina, myo-
cardial infarction
24 of 93 
(25.8)
Healthy 
controls
2 of 42 
(4.8)
EDTA blood Phenol-
chloroform
Hemi-nested 
pstI cloned 
fragment
Smieja, 2001 
[27]
Canada Coronary Angiography 
or angioplasty
22 of 187 
(11.8)
Normal 
angiogram
2 of 21 
(9.5)
8 mL BD CPTc 
tube
QIAamp Nested 
MOMP
Wong, 1999 
[28]
United 
Kingdom
Coronary Angiography 79 of 913 
(8.7)
Normal 
angiogram
21 of 292 
(7.2)
4–5 mL EDTA 
blood
Phenol-
chloroform
Nested 
MOMP
a PCR, polymerase chain reaction b EDTA, ethylene diamine tetra-acetic acid c MOMP, major outer membrane protein d HSP, heat shock protein e 
CPT, BD cell preparation tube (BD Vacutainer Systems, Franklin Lakes NJ, USA)
Table 2: Studies without controls of Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells
Reference Country Study group Prevalence (%) Blood sampling DNA Extraction PCRa target
Blasi, 1999 [30] Italy Aortic aneurysm 19 of 41 (46.3) 8 mL CPTc tube Phenol-chloroform Nested MOMPd
Blasi, 2000 (abstract) Italy COPDe 10 of 21 (47.6) 8 mL CPT tube Not stated Not stated
Bodetti 2000 [34] Australia Blood donors 10 of 60 (16.7) 9 mL EDTA Not stated Nested MOMP
Haranaga, 2001 [36] USA Blood donors 21 of 237 (8.9) 5 mL EDTA QIAamp DNA extraction Touchdown 16S 
rDNA
Iliescu, 2000 [33] Canada Dialysis 33 of 55 (60.0) 10 mL heparin QIAamp DNA extraction 53 kDa protein
Maass, 2000 [29] Germany Unstable angina, 
myocardial infarction
65 of 238 (27.3) 8 mL EDTAb, 
CD14+ cell selection
QIAamp DNA extraction Nested pstI 
cloned fragment
Rassu, 2001 [35] Italy Blood donors 78 of 169 (46.2) 8 mL EDTA Phenol-chloroform Nested MOMP
Smieja, 2002 [32] Canada COPD 24 of 100 (24.0) 8 mL CPT tube QIAamp DNA extraction Nested MOMP
Taylor-Robinson, 
2000 [31]
United 
Kingdom
Peripheral vascular 
disease
Not stated 
(47.0)
Not stated Not stated Not stated
a PCR, polymerase chain reaction. b EDTA, ethylene diamine tetra-acetic acid c CPT, BD cell preparation tube (BD Vacutainer Systems, Franklin 
Lakes NJ, USA) d MOMP, major outer membrane protein e COPD, chronic obstructive pulmonary diseaseBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/21
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A number of investigators have corroborated Boman et
al's observation of circulating C. pneumoniae DNA in pe-
ripheral blood of cardiac patients, albeit with widely var-
ying estimates of prevalence (Table 1). We identified eight
other studies, including seven published manuscripts
[21,23–28]. and one abstract (Da Costa et al, Proceedings
of the Fourth Meeting of the European Society for
Chlamydia Research, Helsinki, Finland, 2000), in which
cardiovascular patients were compared with controls.
These included patients undergoing coronary angiogra-
phy or angioplasty, vascular patients, patients with acute
myocardial infarction or unstable angina, and patients
with carotid atherosclerosis at ultrasonography. Controls
consisted of blood donors, medical students, apparently
healthy controls, or patients with normal coronary angi-
ograms.
The largest of these nine studies examined 1,205 British
patients undergoing coronary angiography, and was con-
ducted by Wong et al [28]. They found a prevalence of
8.7% in patients with angiographically-proven coronary
artery disease, versus 7.2% in those with normal coronary
arteries. In sub-group analysis, they found an association
between coronary atherosclerosis and C. pneumoniae DNA
detection in men but not in women. However, the preva-
lence of smoking was higher in male cases (78%) than in
controls (67%), whereas prevalence was similar in female
cases (53%) and controls (51%).
We examined the nine studies by meta-analysis (Figure 1),
and found a pooled prevalence of 252 of 1763 (14.3%) in
cardiovascular disease patients versus 74 of 874 (8.5%) in
controls. The results were not statistically heterogeneous
(Breslow-Day X2 = 12.3 on 8 degrees of freedom, P=
0.14). The pooled odds ratio, using a random effects mod-
el, was 2.03 (95% CI: 1.34, 3.08, P < 0.001), as illustrated
in Figure 1. Thus, without adjustment for other cardiovas-
cular risk factors, cardiovascular patients had a higher
over-all prevalence of circulating C. pneumoniae DNA than
controls subjects.
Prevalence in other studies
In Table 2, we summarize nine other identified studies
which examined the prevalence of C. pneumoniae DNA in
PBMC. In three studies of cardiovascular disease [29–31],
prevalences of 27.3% to 47.0% were observed. In two
studies of chronic obstructive pulmonary disease, preva-
lences of 24.0% [32] and 47.6% (Blasi et al, Proceedings
of the Fourth Meeting of the European Society for
Chlamydia Research, Helsinki, Finland, 2000) were ob-
served. The highest prevalence, 60.0%, was found in a
small study of patients undergoing peritoneal dialysis
[33]. Among blood donors, prevalence was 16.7% in Aus-
tralia [34], 46.2% in Italy [35], and 8.9% in the United
States [36]. The studies by Bodetti and Timms [34], and by
Haranaga et al [36], both corroborated PCR results by de-
tection of C. pnuemoniae-specific antigen in circulating
mononuclear cells.
Correlation of Chlamydia pneumoniae DNA detection in 
PBMC and in atheroma
We identified two studies in which DNA was sought con-
currently in atheroma and in PBMC [21,30]. Blasi et al ex-
amined 41 patients undergoing aortic surgery [30].
Sixteen patients had C. pneumoniae DNA detected concur-
rently in the resected aneurysmal tissue and in PBMC,
three in PBMC alone, and one in arterial wall alone. Thus,
16 of 17 (94.0%) of patients with C. pneumoniae in arterial
wall were identified by PCR of PMBC.
Berger et al examined PBMC and resected arterial tissue
from 60 vascular disease patients, including carotid and
peripheral arteries and aortic aneurysms [21]. C. pneumo-
niae DNA was detected in 12 plaques. Five of these 12
(42.0%) were also PBMC DNA positive. Conversely, 5 of
12 (42.0%) PBMC DNA positive patients were also DNA
positive in plaques. No statistically significant correlation
between C. pneumoniae DNA presence in plaque or PBMC
was found. Furthermore, there was also no correlation be-
tween the amount of C. pneumoniae DNA in plaques and
in PBMC.
Relation to age and gender
A putative relationship between age and PBMC DNA prev-
alence was found by Bodetti and Timms [34], with highest
prevalence in patients < 35 years (5 of 22, 23%) and > 50
years (3 of 13, 23%) compared with those aged 35 to 50
(2 of 25, 8%), but the sample sizes are too small to allow
meaningful inference. Berger et al [21] found that younger
patients (mean 59 versus 68 years, P < 0.05) were more
likely to have C. pneumoniae DNA in PBMC. By contrast,
Iliescu et al [33] found an association between older age
and C. pneumoniae DNA detection (62.5 versus 51.9 years,
P = 0.01), whereas Haranaga et al [36] found a lower prev-
alence among older blood donors. No clear relationship
with gender was identified in any study.
Relationship to smoking
A relationship between smoking and C. pneumoniae IgG or
IgA seropositivity or titre level has been previously dem-
onstrated [37,38]. Boman et al found an increased preva-
lence of smoking among patients with C. pneumoniae
DNA in PBMC, although the association was not statisti-
cally significant [22]. Smieja et al found a strong and sta-
tistically-significant relationship between C. pneumoniae
DNA in PBMC and smoking, with 10.0% prevalence in
non-smokers, 9.0% in former smokers, and 25.0% preva-
lence in current smokers [27]. In that study, current smok-
ing was associated with C. pneumoniae DNA positivity
independent of age, gender, and season (OR = 4.5, P =BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/21
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0.004). This relationship was recently confirmed in
COPD patients, in whom current smoking was associated
with C. pneumoniae DNA detection in PBMC or sputum
(OR = 2.6, P = 0.04) [32]. Of interest, Berger et al found a
relationship between current smoking and the presence of
chlamydial DNA in atherosclerotic plaque [21].
Relationship to season
Smieja et al found a strong relationship between C. pneu-
monia DNA detection and season. Among cardiology,
respirology and family practice patients in studies span-
ning four separate Canadian winter seasons [27,32]
(Smieja et al, unpublished), seasonal variation in preva-
lence was seen with highest prevalence between February
and April (OR = 3.6 to 6.2), and lowest prevalence be-
tween June and October. No other reported study has ad-
equately examined seasonal prevalence, but potential
inter-month differences were noted in three studies. Rassu
et al [35] reported higher prevalence among Italian blood
donors in February (57.6%) compared with October
(37.9%). Haranaga et al [36] found a lower prevalence in
October and November (0 of 137, 0.0%) compared with
August or September (21 of 100, 21.0%). Berger et al re-
ported that aneurysmal plaque was DNA positive more of-
ten in May (25.0%) or June (50.0%) than in July to
October (0.0 to 8.0%, P < 0.05).
Blood sampling, extraction, and amplification
Blood sampling, extraction, and PCR targets are summa-
rized in Tables 1 and 2. Generally, Ficoll-hypaque centrif-
ugation of 5 to 10 mL of EDTA blood was used to isolate
PBMC. In four studies by two research groups, cell prepa-
ration tubes (CPT, BD Vacutainer Systems, Franklin Lakes
NJ) were used. No studies were found for a direct compar-
ison between Ficoll-hypaque and CPT methods.
Study investigators sampled 200–1000 L of PBMC, ex-
tracted into a volume of 40–200 L, and used 3–50 L for
the PCR reaction. Thus, a total volume of 0.15 to 2.50 mL
of whole blood was sampled in the final PCR(s) of these
various studies. Among eight studies in which sufficient
details were given to calculate the total blood sampled,
higher DNA prevalence was associated with greater sam-
pled blood volume (X2 for linear trend = 55.0, P < 0.001).
Two methods were used for DNA extraction from PBMC:
phenol-chloroform or Qiagen QIAamp DNA mini-kits.
Examining only cardiovascular patients to enable valid
comparison, prevalence was 188 of 1195 (15.7%) extract-
ed with phenol-chloroform, compared with 64 of 568
(11.3%) extracted with Qiagen columns (mean difference
= 4.5%, 95% CI: 1.1 to 7.8%).
Eight of 18 studies used a nested PCR based on the ompI
gene of the major outer membrane protein (MOMP) de-
scribed by Tong and Sillis [39], whereas other studies used
a variety of nested and non-nested PCRs targeting MOMP,
16s DNA, heat shock proteins, or other targets. Examining
only cardiovascular patients, prevalence was higher using
the Tong and Sillis nested MOMP PCR (95 of 316, or
30.1%) than with the remaining assays (143 of 1214, or
11.8%), with mean difference = 18.3%, 95% CI: 12.9,
Figure 1
Meta-analysis of circulating Chlamydia pneumoniae DNA detection in cardiovascular studies with controls. Odds ratios with
95% confidence intervals and pooled odds ratios calculated under a random effects model (Review Manager 4.04).BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/21
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23.7). However, the latter group was heavily influenced
by the low prevalence of 79 of 913 (8.7%) in one study
[28], which used a nested assay directed at a different
MOMP target.
Discussion
Epidemiologic issues
Two studies examined whether C. pneumoniae DNA de-
tection in PBMC correlated with its presence in atheroscle-
rotic plaque, and reached different conclusions. Further
studies are required to validate circulating DNA detection
as a surrogate for bacterial presence within atherosclerotic
plaque.
The prevalence of C. pneumoniae DNA detection in PBMC
was found to vary widely: between 0.0% and 46.0%
among controls, and between 4.2% and 59.4% in patients
with cardiovascular disease. Using meta-analysis, we dem-
onstrated that circulating DNA prevalence was higher
among cardiovascular patients than among controls.
However, lack of adjustment for potentially confounding
variables such as smoking, season, age and gender may
negate these results. Indeed, in a recent study of 310 coro-
nary angiography patients and 102 concurrently-recruited
family practice controls, adjusting for smoking and sea-
son, we found that C. pneumoniae DNA prevalence was
less common among heart disease patients than in con-
trols (Smieja et al, unpublished). Addition of this unpub-
lished study would result in a non-significant association
between C. pneumoniae detection and cardiovascular dis-
ease (pooled OR = 1.6, 95% CI: 0.7, 3.5, P = 0.22). Further
studies with concurrent controls, matched or adjusted for
age, gender, smoking and season, are required to conclude
whether C. pneumoniae DNA detection is associated with
cardiovascular disease.
We caution that meta-analysis of non-randomized data
may be quite misleading due to heterogeneity of the con-
trol groups. Possible explanations for the found associa-
tion include selection bias, publication bias, confounding
by other cardiovascular risk factors, or a true association
(whether causal or innocent) between C. pneumoniae and
atherosclerosis. Selection bias may be acting in the selec-
tion of cases (which represent primarily patients with
prevalent, chronic disease and not incident cases), or in
the selection of controls. The use of blood donors as con-
Figure 2
Funnel plot of Chlamydia pneumoniae DNA detection (Review Manager 4.04). Precision of estimate (reciprocal of standard
error) versus odds ratio for studies of circulating C. pneumoniae DNA detection by cardiovascular disease status compared
with disease-free controls. The dotted line indicates the pooled odds ratio of the studies at 2.0. The curve illustrates a funnel
plot centred about the most precise study, in which an equal number of studies are expected in the left and right tails. Asym-
metry of the funnel plot suggests publication bias, or bias in selection of cases or controls.
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trols selects a group in whom many cardiovascular risk
factors are less prevalent than in the general population. A
second possible bias is of publication bias, in that positive
results may have been more likely to get published. This is
suggested by examination of a funnel plot (Figure 2), in
which the estimated odds ratio of the association between
C. pneumoniae DNA detection and vascular disease is
graphed against the precision of the estimate. Ordinarily,
a funnel shaped with the apex in the middle of the funnel
should be seen, as indicated on the diagram [40]. The lack
of symmetry in the graph suggests that there may be a
number of unpublished studies in existence, or that bias
in the selection of cases or controls may be playing a role.
Confounding may be playing an important role in any
found association with cardiovascular disease. We dem-
onstrated a strong association between PBMC C. pneumo-
niae DNA detection and current smoking status [27], and
Berger et al [21] demonstrated that current smokers are
more likely to have C. pneumoniae DNA in atherosclerotic
plaque. A more detailed smoking history, or laboratory
measures of smoking metabolites such as plasma coti-
nine, may be useful to better control for confounding by
smoking status.
We also found a strong association with Canadian winter
or spring season in three of our studies [27,32] (Smieja et
al, unpublished), with highest prevalence between Febru-
ary and April. Studies by Rassu et al [35] and Berger et al
[21] suggest similar seasonal patterns in Italy and Germa-
ny, respectively. Seasonal differences may be due to sea-
sonal occurrence of acute C. pneumoniae infections in the
community, reactivation of chronic infection, or, poten-
tially, to seasonal differences in DNA extraction efficiency
or PCR assay performance. Most studies did not recruit for
sufficiently long to observe seasonal patterns, and studies
from various geographic locations are required to deter-
mine whether seasonality is a wide-spread phenomenon.
Of interest, Boman et al's original study [22] recruited pa-
tients between April and May 1998. Similarly, other high
prevalence studies ( 40.0%) such as Iliescu et al [33]
(April to May, 1999), and Blasi et al [30] (December 1998
to February 1999) recruited during times these "high prev-
alence" months. Conversely, Wong et al [28] recruited be-
tween August 1998 and March 1999, and found
prevalence of only 8.7%.
Important implications of this seasonal hypothesis are
that prevalence will be lowest between June and October,
and that controls for patients need to be carefully recruit-
ed with matching by month. Berger et al's observation of
a peak in C. pneumoniae DNA in atheroma during June
[21], and of a lack of correlation with concurrent PBMC
DNA, suggests that there may be some delay between
PBMC DNA detection and its presence in atheroma. How-
ever, Berger et al did not sample between January and
April, months during which C. pneumoniae DNA preva-
lence may have been higher in both PBMC and in athero-
ma, and during which time a better correlation might
have been found between the two sites.
In summary, these data suggest that C. pneumoniae DNA
detection in PBMC should be performed, as a minimum,
during winter and spring months, and controlled for
smoking status. Any comparisons with controls should
also be controlled for age and gender, although the rela-
tionship between these factors and C. pneumoniae DNA
prevalence remains unclear.
Laboratory issues
Boman and colleagues have reviewed many of the techni-
cal aspects of C. pneumoniae DNA amplification in general
[8,41], and of PBMC DNA detection in specific [42]. In
this review, we examined four important differences in
technique which require further investigation: the volume
of blood sampled, type of blood specimen used, DNA ex-
traction methods, and PCR primers.
We found that the total volume of blood sampled in the
PCR reaction was related to higher detection. We previ-
ously demonstrated a relationship between low copy
numbers and the proportion of PCR replicates that were
positive [43]. Solutions to this sampling problem include
extracting a large volume of blood, and doing replicate
PCRs to maximize detection. However, with larger vol-
umes, inhibitors will also be more concentrated. This may
be overcome by testing different concentrations.
Commercial products are now available to simplify and
standardize three aspects of testing: BD Vacutainer CPT
tubes for blood collection as an alternative to Ficoll-hy-
paque gradient centrifugation, Qiagen QIAamp DNA
mini-kits as an alternative to phenol-chloroform extrac-
tion, and a new commercial PCR assay from Abbott Lab-
oratories. The commercial products save labour time but
are more expensive. Our review suggests that phenol-chlo-
roform extraction may have a higher yield than Qiagen
columns, but inter-study comparisons may be misleading
and a direct comparison is needed to validate this finding
with paired samples. Experience with a commercial PCR
assay has been published, and may enable meaningful
comparisons between centres in the future [44].
A MOMP nested PCR described by Tong and Sillis [39]
was used in half of the identified studies. Somewhat high-
er prevalence was seen with this PCR than with other
primers, but no firm conclusions should be based on a
comparison between studies that used heterogeneous
populations. However, they are in accord with our parallelBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/21
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comparison of five in-house published PCRs, in which we
found that the Tong and Sillis nested PCR had superior
clinical sensitivity for C. pneumoniae in PBMC despite sim-
ilar analytical sensitivity [45].
Confirming the presence of Chlamydia pneumoniae in 
PBMC
Regardless of the best "screening" test for detecting C.
pneumoniae DNA in PBMC, additional methods of con-
firming the identification of C. pneumoniae are desirable
[42]. Such confirmation would ensure the early identifica-
tion of false-positive tests, and ensure valid comparisons
between tests. However, simply confirming that circulat-
ing C. pneumoniae nucleic acids are present does not imply
that their detection is clinically relevant. Rather, confirma-
tion is required to define an appropriate molecular meas-
ure for prospective clinical studies.
There is good evidence that C. pneumoniae circulates in the
bloodstream as a cell-associated infection. We [27] and
others [34] have demonstrated that the plasma fractions
of PBMC-positive patients were uniformly negative for C.
pneumoniae DNA. However, it remains unclear which cells
within the peripheral blood mononuclear cell layer con-
tain C. pneumoniae. Peripheral blood mononuclear cells
contain monocytes, dendritic cells, and lymphocytes, and
may be contaminated with polymorphonuclear cells or
platelets. Using CD14 monoclonal selection, Maass et al
[29] demonstrated a prevalence of 27.0% C. pneumoniae
DNA positivity among patients presenting to hospital
with acute coronary syndromes. It is unknown whether
this prevalence was higher than in whole blood or buffy
coat alone. Kaul et al [24] used adherence to select CD14
cells and found that the CD3+ lymphocytes fraction was
positive more often (10 of 28 patients, 35.7%) than the
"adherent" fraction of CD14+ cells (3 of 28, 10.7%). Fur-
ther work is required to determine which cells are infect-
ed, and whether cell enrichment would improve detection
compared with mononuclear cell preparations.
Potential methods for confirming whether C. pneumoniae
is present in PBMC include use of a second DNA-based
amplification test, use of RNA-based methods, or detec-
tion of antigen. These will be discussed in the same order.
As more sensitive methods are developed, an alternate
DNA-based nucleic acid amplification test with a different
amplification target may be used to confirm a specimen as
a true positive. However, due to low copy number and
sampling error, confirmation of only 30–80% of such
samples should be expected [14,43]. Use of higher blood
volumes and extraction of a greater proportion of infected
cells may improve initial detection as well as confirma-
tion.
Development of methods of quantitating C. pneumoniae
in whole blood and PBMC have been developed using
TaqMan or LightCycler real-time PCR detection technolo-
gies, and Berger et al used a quantitative assay for the de-
tection of C. pneumoniae DNA in PBMC and
atherosclerotic plaque [21]. Three replicates were run per
specimen, and the number of negative runs was not re-
ported. In our experience, only one of three replicates are
positive in the majority of patients, indicating very low
copy number [27,43]. For such patients, quantitative
methods are unlikely to improve detection, although
studies of quantitation versus clinical importance may be
informative.
Alternatively, RNA targets may be used for confirmation
of C. pneumoniae PBMC positivity. Gieffers et al [46] re-
ported the use of a reverse transcriptase PCR (RT-PCR) tar-
geting 16S RNA transcript, and demonstrated active RNA
production by infected PBMC. In volunteers who took an-
tibiotics prior to blood sampling, RNA was still detected,
indicating that viable chlamydia were present and that an-
tibiotics had not suppressed chlamydia in infected PBMC.
Conversely, as with DNA-based validation, RNA-based
confirmation is likely subject to the same sampling prob-
lems.
An attractive alternative would be to use a different tech-
nology for detection of C. pneumoniae in PBMC. Bodetti
and Timms [34] described the detection of circulating C.
pneumoniae antigen in PBMC using a specific monoclonal
antibody. Ten of 10 PCR positive PBMC specimens were
also antigen positive, compared with zero of ten PCR neg-
ative specimens. Antigenemia was also assessed and re-
ported in a recent paper by Haranaga et al [36]. Wider
experience with the sensitivity and specificity of this tech-
nique is required, and while it may emerge as a confirma-
tory test, the method is technically difficult and not
suitable for a screening test.
Conclusions
The detection of C. pneumoniae DNA in PBMC was associ-
ated with CV disease in unadjusted case-control studies, as
summarized in this review, and is a promising test for fur-
ther molecular epidemiologic studies. To verify this dis-
ease association, future studies will need to match or
adjust for potential confounding by smoking, season, age,
and gender.
To ascertain the role of C. pneumoniae in cardiovascular
disease and other chronic diseases, epidemiologists and
other researchers need a sensitive, specific, and reproduc-
ible test that correlates with the endovascular presence of
C. pneumoniae. To improve the sensitivity of PBMC test-
ing, we recommend using the nested MOMP PCR and
sampling large blood volumes. Studies are needed to op-BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/21
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timize blood volumes and extraction methods, and to fur-
ther validate circulating C. pneumoniae DNA detection as a
surrogate marker for its presence in atheroma.
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